BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 19576124)

  • 21. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
    Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
    Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
    Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
    Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ
    Cancer; 2012 Nov; 118(21):5278-82. PubMed ID: 22517268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prognostic significance of blood count at the time of achieving morphologic leukemia-free state in adults with acute myeloid leukemia].
    Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):185-191. PubMed ID: 28395440
    [No Abstract]   [Full Text] [Related]  

  • 25. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Study of clinical outcome and analysis of prognosis related factor in children with acute myeloid leukemia].
    Zou Y; Wang H; Chen XJ; Wang SC; Zhang L; Chen YM; Zhu XF
    Zhonghua Xue Ye Xue Za Zhi; 2006 Sep; 27(9):621-5. PubMed ID: 17278430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment responses, outcomes, and prognostic factors associated with them in patients with secondary acute myeloid leukemia].
    Ma L; Zhao T; Chen YY; Jiang H; Xu LP; Zhang XH; Wang Y; Sun YQ; Mo XD; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):124-131. PubMed ID: 36948866
    [No Abstract]   [Full Text] [Related]  

  • 29. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
    Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
    Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.
    Ollila TA; Olszewski AJ; Butera JN; Quesenberry MI; Quesenberry PJ; Reagan JL
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):204-209. PubMed ID: 29433979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy.
    Brandwein JM; Gupta V; Schuh AC; Schimmer AD; Yee K; Xu W; Messner HA; Lipton JH; Minden MD
    Am J Hematol; 2008 Jan; 83(1):54-8. PubMed ID: 17696207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term survival results according to cytogenetic risk in patients with acute myeloid leukemia--singl center experience].
    Piatkowska-Jakubas B; Mensah-Glanowska P; Salamańczuk Z; Skotnicki AB
    Przegl Lek; 2011; 68(6):291-5. PubMed ID: 22039664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
    Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
    Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.
    Nomdedéu JF; Hoyos M; Carricondo M; Bussaglia E; Estivill C; Esteve J; Tormo M; Duarte R; Salamero O; de Llano MP; García A; Bargay J; Heras I; Martí-Tutusaus JM; Llorente A; Ribera JM; Gallardo D; Aventin A; Brunet S; Sierra J;
    Leukemia; 2013 Nov; 27(11):2157-64. PubMed ID: 23584566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of CD56 antigen expression in acute myeloid leukemia.
    Di Bona E; Sartori R; Zambello R; Guercini N; Madeo D; Rodeghiero F
    Haematologica; 2002 Mar; 87(3):250-6. PubMed ID: 11869936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy and safety of the HAA regimen as induction chemotherapy in 236 de novo acute myeloid leukemia].
    Ye PP; Mu QT; Chen FF; Mai WY; Meng HT; Qian WB; Tong HY; Huang J; Tong Y; Chen ZM; Lou JY; Wang YG; Ni WM; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):825-9. PubMed ID: 24171953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
    Kornblau SM; Vu HT; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May WS
    Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.